Mesenchymal stem cell-derived exosome miR-542-3p suppresses inflammation and prevents cerebral infarction

Guofeng Cai 1*, Guoliang Cai 2,3, Haichun Zhou 1†, Zhe Zhuang 1, Kai Liu 1, Siying Pei 1, Yanjun Wu 1, Hong Wang 1, Xin Wang 1, Shengnan Xu 4, Cheng Cui 4, Manchao Sun 4, Sihui Guo 4, Kunping Jia 1, Xiuzhen Wang 1 and Dianquan Zhang 5†

Abstract

Background: Cerebral infarction ranks as the second leading cause of disability and death globally, and inflammatory response of glial cells is the main cause of brain damage during cerebral infarction.

Methods: Studies have shown that mesenchymal stem cells (MSCs) can secrete exosomes and contribute to cerebral disease. Here, we would explore the function of MSC-derived exosome in cerebral infarction.

Results: Microarray indicated a decrease of miR-542-3p and an increase of Toll-Like Receptor 4 (TLR4) in middle cerebral artery occlusion (MCAO) mice comparing with sham mice. And luciferase and RIP analysis indicated a binding of miR-542-3p and TLR4. Then, we injected AAV9-miR-542-3p into paracele of sham or MCAO mice. Functional analysis showed that AAV9-miR-542-3p inhibited infarction area and the number of degenerating neurons and suppressed inflammatory factors’ expression and inflammatory cell infiltration. As well, transfection of miR-542-3p mimics into HA1800 cells underwent oxygen and glucose deprivation (OGD). Similarly, overexpression of miR-542-3p alleviated OGD induced cell apoptosis, ROS, and activation of inflammation response. Moreover, miR-542-3p could be packaged into MSCs and secreted into HA1800 cells. The extractive exosome-miR-21-3p treatment relieved MCAO- or OGD-induced cerebral injury and inflammation through targeting TLR4.

Conclusion: These results confirmed that MSC-derived exosome miR-542-3p prevented ischemia-induced glial cell inflammatory response via inhibiting TLR4. These results suggest possible therapeutic strategies for using exosome delivery of miR-542-3p to cure cerebral ischemic injury.

Keywords: Cerebral infarction, Inflammation, Exosome, MicroRNA, MSC

* Correspondence: cangjiong1973@163.com
† Dianquan Zhang and Haichun Zhou contributed equally to this study as co-first authors.

1 Hanan Branch of Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin 150001, China

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Cerebrovascular disease is a kind of disease with acute neurological disease and common system, which has the characteristics of high fatality rate, disability rate, and recurrence rate [1]. According to the data released by the World Health Organization, stroke has become the second leading cause of death worldwide in the past 10 years from 2000 to 2012 [2]. Among them, ischemic cerebral infarction is the most common type of stroke, which occurs after cervical or cerebral blood flow is blocked [3]. Due to the active metabolism of the brain, more oxygen is needed. Once the blood flow is blocked and the perfusion cannot be restored in a short period of time, the brain cells will die due to hypoxia, which in turn induces brain dysfunction [4]. Although the function of surviving neurons can at least partially compensate for brain damage after ischemia, the repair ability of human brain neurons is limited [5]. At present, thrombolysis is the most effective method for the clinical treatment of ischemic stroke, but thrombolysis has a strict treatment time window, and the vast majority of patients have lost the opportunity of thrombolytic therapy when they are admitted to hospital [6]. Therefore, finding new therapeutic targets is of great significance for the treatment of ischemic stroke.

Inflammatory response is one of the important mechanisms of dysfunction caused by cerebral infarction [7, 8]. Ischemia induces the release of pro-inflammatory cytokines (TNFα, IL-1, IL-6, MCP1) and inflammatory mediators (ROS and NOS) from glial cells and endothelial cells [9–11]. These cytokines recruit leukocytes and stimulate the production of adhesion molecules on leukocytes and endothelial cells, causing phagocytic activity and immune response [9]. It has been confirmed that IL-1 releases arachidonic acid and increases the number of TNFα and IL-1β, which leads to the accumulation of inflammatory cells and aggravates brain injury [13]. Therefore, the understanding of inflammatory response is very important to understand the pathogenesis and explore the treatment of hypoxic-ischemic brain injury.

Exosomes originate from cellular polyvesicles [14]. After combining with the plasma membrane, exosomes can be secreted out of cells. Almost all types of cells can secrete exosomes, which are widely distributed in body fluids, in which there are intracellular sources of lipids and RNA and other bioactive substances [15]. Exosomes can mediate intercellular communication, and it has been confirmed in recent studies that exosomes can participate in the remodeling process after cerebral infarction by mediating nucleotide and protein affecting angiogenesis and neuroglia [16, 17]. At present, exosomes in the treatment of cerebral infarction is still limited to clinical research, mainly in stem cell expression of related genes and transport-related regulatory proteins. In addition, as a drug delivery carrier, therapeutic drugs are transferred into the exosomes by means of electroporation to effectively achieve the purpose of treatment [18]. When exosomes played a role in stem cell expression of related genes and transport-related regulatory proteins, the motor function of non-exosome-related model mice derived from stem cell (MSCs) recovered significantly. Exosomes or the basis of MSC-mediated miR-133b can effectively improve the neurite remodeling of ischemic model mice and restore the function of model mice [19]. In addition, exosomes can also play a full role on the basis of transport-related regulatory proteins. Exosomes released by MSC have been found to contain TNFα proteins [20]. Proteomic analysis has proved that exosomes released by MSC have the effect of angiogenin paracrine, which indicates that exosomes released by MSC have the role and great potential in the treatment of ischemic tissue-related diseases [21, 22].

In recent years, related studies have shown that miRNAs play an important role in all stages of the process of cerebral ischemic injury and can aggravate or alleviate brain injury in a variety of ways [23]. Chi et al. have confirmed that overexpression of miR-134 aggravates cell death and apoptosis in vivo and in vitro [24]. When miR-134 was deficient, the level of HSPA128 protein increased in N2A cells treated with oxygen and glucose deprivation and ischemic brain tissue. MiR-134 deficiency can reduce the cerebral infarction area and nerve cell injury and improve the neurological function score in mice. Sun et al. found that overexpression of miR-124 significantly increased the infarct size of the mouse model of middle cerebral artery ischemia, while knock-out of miR-124 significantly reduced the infarct size [25]. MiR-124 plays a neuroprotective role by inhibiting apoptosis in the pathological process of ischemic stroke. MiR-542-3p is mainly studied in tumors, also expressed in brain tissues [26]. And He et al. indicated that miR-542-3p might regulate pathological processes of ischemic stroke [27]. However, the role of miR-542-3p in cerebral infarction is poorly identified. Herein, we explored the effect of miR-542-3p in cerebral infarction-induced glial cell inflammation and injury and clarify whether miR-542-3p could be packaged into exosomes to treat cerebral infarction.

Methods
Animal experiments
Middle cerebral artery occlusion (MCAO) of mice used for cerebral infarction model. As previously described [28], left distal middle cerebral artery was occluded after the mice were completely anesthetized. The mice in the sham group only received vascular separation without ligation. One hundred-microliter AAV9-miR-542-3p/
AAV9-miR-NC (2.0 × 10^{11} GC/ml) was injected into paracel of mice at 1 h after MCAO or sham operation. Neurological assessment used to determine neurological deficiency of mice at 3 days after MCAO operation [29]. The left hemispheres of the mice were extracted, and the brain tissue water content was detected as previously described [30]. The research protocol of this study was approved by the Animal Care and Use Committee of the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine.

**Cell culture and treatment**

The MSCs and HA1800 cells (human glial cells) were purchased from the Science Cell Laboratory. Cell lines were cultured in DMEM (Thermo-life, USA) with 10% FBS (Thermo Fisher, USA) and 100 μL/mL penicillin and streptomycin (Beyotime, China) and placed at 37°C with 5% CO2. The HA1800 cells were plated until the cell density reached 80% confluence of dishes to transflect. MiR-542-3p mimics and Toll-Like Receptor 4 (TLR4) plasmid were constructed by Genechem (Shanghai, China) and transfected into cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For oxygen and glucose deprivation (OGD), HA1800 cells were seeded in Hank’s medium and cultured at 37°C with 5% CO2 and 95% N2 for 2 h.

**Exosome isolation and identification**

Exosomes in supernatant of MSCs transfected with miR-542-3p/miR-NC were isolated, and several centrifugations were performed to purify exosomes [31]. Transmission electron microscopy (TEM) was used to identify exosomes structure. The diameter of exosome was examined by particle size analysis, and exosome marker protein CD63, CD9, and GM130 were tested by western blot.

**MTT assay**

HA1800 cells were plated in 96-well plates, and we used MTT assay to detect the cell viability. MTT (0.5 mg/mL; Beyotime Biotechnology, China) was added to every well after treatment and incubated for 3 h at 37°C. And 150 μL DMSO was added and incubated for 15 min. We measured the absorbance by Spectrophotometer (Tecan, Austria) at 493 nm.

**ROS assay**

Reactive oxygen species (ROS) detection was performed according to the procedures (Beyotime, China). Briefly, HA1800 cells were plated in 12-well plates and ROS solution was added into cells for 20 min. After fixation in 4% paraformaldehyde and PBS washing solution, the cells were incubated in DAPI for 10 min. Fluorescence was observed by fluorescence microscope.

**qRT-PCR**

RNA extraction was performed using trizol reagent. NanoDrop 8000 (Thermo Scientific, Waltham, MA, USA) was used to detect the concentration and purity of RNA. The single-stranded cDNAs were synthesized from 1 μg of RNA. The expression of mRNAs and miRNAs were quantified by RT-PCR with SYBR Green I (Thermo Fisher Scientific, Inc).

**Western blot**

Tissues, cells, or exosomes were assayed at the indicated times, prepared with SDS lysis buffer (Beyotime, China), and centrifuged at 14,000×g at 4°C. Proteins were separated using 10% or 15% polyacrylamide gels and transferred onto 0.22-μm PVDF membranes (Merck Millipore, USA). The total amount of protein samples is 50 μg, 30 μg, and 60 μg for exosome, cell, and tissue protein detection, respectively. The membrane was blocked with 5% BSA for 1.5 h. The first incubation and second incubation were carried out according to the operation step. The expression of the protein was expressed by the grey value. Primary antibodies list: CD63 (ab134045, Abcam), CD9 (ab92726, Abcam), GM130 (ab52649, Abcam), GADPH (ab181602, Abcam), TLR4 (ab22048, Abcam), TNFα (17590-1-AP, Proteintech), IL 6 (66146-1-Ig, Proteintech). The secondary antibodies IRDye700/800 Mouse or Rabbit were produced by LICOR (Lincoln, Nebraska, USA).

**Luciferase assay**

HEK293 cells were co-transfected with 20 mmol/L miR-542-3p mimic or miR-NC together with WT-TLR4/Mut-TLR4. Luciferase activity was measured with Dual Luciferase Reporter Assay Kit (Transgene, China) on GloMax20/20 at 48 h after the transfection.

**RIP**

We used RIP assay to determine the binding between TLR4 and miR-542-3p using Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore) as previous study [32]. Briefly, HA1800 cells were transfected with biotinylated TLR4, and the mRNA level of miR-542-3p was detected using qRT-PCR.

**H&E staining**

The brain tissues were gathered and fixed in 4% paraformaldehyde for 24 h. Then, the fixed tissues were embedded in paraffin. Next, Paraffin slicer machine was used to cut slices (5-mm cross-sectional). H&E staining was used to evaluate pulmonary morphology. Liver sections were dewaxed with xylene and treated with ethanol at different concentrations for 5 min. Hematoxylin staining for 5 min, 5% acetic acid treatment for 1 min, water rinse. Dye with eosin for 1 min, rinse with running
water. Dehydrate in 70%, 80%, 90%, 100% ethanol for 10 s, xylene for 1 min. Drizzle with neutral gum and seal.

TTC staining
TTC staining was used to evaluate the infarcted size of the brain. The brain sections were placed in the smallest vessel containing 2% TTC staining solution (G3005, Solarbio) and incubated at 37 °C in darkness for 15–30 min. The color changes of the samples were observed while incubating. The excess staining solution on the tissue surface was rinsed off with PBS and photographs were taken.

Immunohistochemistry (IHC) staining
Paraffin sections of brain tissues from different groups were dewaxing to water in xylene and descending series of ethanol. We penetrated sections using 0.5% Triton X-100. After 3 times wash, we blocked sections with 50% goat serum. Then, sections were incubated with VEGFA antibody (ab51745, Abcam) overnight. We incubated the sections using secondary antibody. The sections were dehydrated in 70%, 80%, 90%, 100% ethanol for 10 s, xylene for 1 min. Drizzle with neutral gum and seal.

Statistical analysis
Data were shown as mean ± SD. Student’s t test or one-way ANOVA was used to compare the groups. P < 0.05 was considered significance.

Results
miR-542-3p was downregulated during cerebral infarction
We first established mouse model of MCAO at 12 h, 1 days, 3 days, 5 days, and 7 days. Then, FJC staining was used to determine degenerating neurons. FJC staining data showed that the number of degenerating neurons was increased at 12 h and peaked at 3 days after MCAO operation (Fig. 1a), which suggested that we successfully established a cerebral infarction model. Then, we performed microarray analysis, and the data showed the differentially expressed miRNAs in sham and MCAO operation of brain tissues, which showed a decrease of mir-542-3p in infarcted brain tissues (Fig. 1b). Following qRT-PCR analysis indicated that miR-542-3p was decreased after MCAO operation (Fig. 1c). Moreover, microarray analysis showed a significantly increased of TLR4 in MCAO mice comparing with sham mice (Fig. 1d). Then, qRT-PCR also suggested that TLR4 was induced in brain tissues after MCAO surgery (Fig. 1e). Meanwhile, bioinformatics analysis of the 3′ UTR of TLR4 predicted a conserved binding site for miR-542-3p. To verify that miR-542-3p interacts with TLR4, luciferase activity was performed in HEK293T cells. Cells transfected with miR-542-3p mimic decreased the luciferase activity in WT-TLR4 not in mutant type, which indicated the relationship miR-542-3p with TLR4 (Fig. 1f). And endogenous TLR4 was enriched in biotinylated miR-542-3p transfected HA1800 cells, which revealed a direct binding of TLR4 with miR-542-3p (Fig. 1g). The abnormal expression of miR-542-3p and TLR4 may be novel target for cerebral infection.

Overexpression of miR-542-3p attenuated MCAO induced cerebral injury
For further research, we constructed adeno-associated virus 9 (AAV9) miRNA for overexpression of miR-542-3p (AAV9-miR-542-3p, AAV9-miR-NC was indicated as a control group) and injected into paracel of mice that underwent with sham or MCAO operation (Fig. 2a). TTC staining showed that higher infarction volume induced by MCAO operation was significantly reduced by AAV9-miR-542-3p administration (Fig. 2b). The brain water content in the MCAO mice was lower after AAV9-miR-542-3p treatment (Fig. 2c). Neurological grading scores of the MCAO mice reduced after the AAV9-miR-542-3p injection (Fig. 2d). FJC staining showed that AAV9-miR-542-3p, but not AAV9-miR-NC, decreased FJC-positive cell numbers upon MCAO surgery (Fig. 2e). Moreover, H&E staining showed that MCAO surgery caused resulted in obvious swelling of the cells, large intercellular space and infiltration of neutrophils, while AAV9-miR-542-3p significantly alleviated the MCAO-induced brain edema and the infiltration of inflammatory cells (Fig. 2f). Considering the importance of revascularization for infarcted brain, VEGFA (the main angiogenic factor) level in brain tissues was tested using IHC. And data showed that MCAO surgery increased VEGFA expression, while AAV9-miR-542-3p injection further significantly promoted the expression of VEGFA (Fig. 2g). And qRT-PCR showed that AAV9-miR-542-3p reduced MCAO-induced increase of inflammatory factors TNFa and MCP-1 (Fig. 2h). As well, MCAO operation induced TNFa and IL 6 protein expression, while AAV9-miR-542-3p reversed the effect of MCAO operation (Fig. 2i). Besides, AAV9-miR-542-3p
injection inhibited TLR4 expression both in sham and MCAO mice (Fig. 2i). These results indicated that miR-542-3p protected against MCAO-induced cerebral injury and inflammation.

**MiR-542-3p alleviated OGD induced glial cell damage**

In vitro, we cultured HA1800 cells treated with OGD to mimic in vivo MCAO operation. And miR-542-3p was transfected into HA1800 cells to force miR-542-3p expression (Fig. 3a). MTT results showed that OGD decreased cell viability, while miR-542-3p recovered cell viability (Fig. 3b). In addition, TUNEL analysis indicated that OGD promoted cell apoptotic numbers, while miR-542-3p decreased apoptotic cell numbers (Fig. 3c). And ROS assay showed that OGD increased ROS production, while miR-542-3p inhibited ROS level in HA1800 cells (Fig. 3d). Moreover, miR-542-3p remitted the promoting effect of OGD on inflammation of HA1800 cells, as well as the expression of TLR4 (Fig. 3e, f). Together, miR-542-3p alleviated OGD-induced glial cell injury.

**MiR-542-3p was packaged into MSC exosomes**

MiRNA in exosomes has attracted much attention due to the protection role of exosomes, and MSCs are a main source of exosomes [34]. In present study, MSCs were transfected with miR-542-3p mimic or miR-NC, and the expression level of miR-542-3p was detected by qRT-PCR (Fig. 4a). Exosomes isolated from supernatant of MSCs were identified by TEM (Fig. 4b), and particle size analysis (Fig. 4c). As well, exosome markers (CD63 and CD9) were detected using western blot (Fig. 4d). Then, the expression of miR-542-3p in isolated exosomes was assessed, which
showed an increase of miR-542-3p after miR-542-3p transfection of MSCs (Fig. 4e). In summary, miR-542-3p can be secreted by MSCs via exosomes.

**Exo-miR-542-3p protected against MCAO-induced cerebral injury**

To illustrate the role of exosomal miR-542-3p (exo-miR-542-3p), we injected exo-miR-542-3p from Fig. 4d into paracel of mice accompanied with or without MCAO. And miR-542-3p in brain tissues was calculated; exo-miR-542-3p injection promoted miR-542-3p expression (Fig. 5a). Following function experiments showed that exo-miR-542-3p decreased infarcted area, brain water content, neurological grading scores, and FJC-positive cell numbers during MCAO surgery (Fig. 5b–e). In addition, exo-miR-542-3p inhibited MCAO-induced brain edema and neutrophils infiltration brain damage and inflammatory response (Fig. 5f–i).

**Exo-miR-542-3p inhibited inflammation and injury via regulating TLR4 in glial cells**

We then treated HA1800 cells with exo-miR-542-3p and OGD and transfected with TLR4 plasmid at the same time. Exo-miR-542-3p treatment increased miR-542-3p expression and inhibited TLR4 level, while TLR4 transfection reversed exo-miR-542-3p effects (Fig. 6a). Functional analysis has been suggested that exo-miR-542-3p increased cell viability and inhibited cell apoptosis, ROS production, and inflammation (Fig. 6b–f). But, TLR4 transfection removed the benefit role of exo-miR-542-3p on HA1800 cells during OGD exposure (Fig. 6b–f). Taken together, exo-miR-542-3p from MSCs inhibited ischemic injury of brain via modulating TLR4.
Discussion

Cerebral infarction is a series of cascade injury reactions caused by the damage of neurovascular components upon ischemia and hypoxia [35]. Cerebral infarction is mainly treated with tissue-type plasminogen activator thrombolytic therapy, but few patients actually recover their neurological function clinically. Exosomes are 40–100 nm in diameter, vesicles encapsulated by lipid bilayer membranes released from cells into the extracellular space [36]. Exosomes and miRNAs can effectively respond to the pathophysiological state of cells, and they have great potential in the diagnosis and treatment of tumors and cardiovascular and other systemic diseases [37]. Present study showed a downregulation of miR-542-3p and upregulation of TLR4 in infarcted brain tissues, and miR-542-3p interacted with TLR4 in HA1800 cells. Functionally, miR-542-3p protected against ischemic injury of brain tissue and nutritional deprivation damage of HA1800 cells. Interestingly, miR-542-3p can be packaged and secreted by MSCs. And exo-miR-542-3p from MSCs also showed a protective effect for MCAO-treated brain tissues or OGD-exposed HA1800 cells via modulating TLR4 level.

MiRNAs is a highly conserved non-coding RNA in eukaryotes [38]. By complementary pairing with the 3′ UTR of the target mRNA molecule, miRNA regulates the expression of target genes at the post-transcriptional level, leading to the degradation or inhibition of the translation of the target mRNA molecule [39]. Through this regulatory relationship, miRNA affects many aspects of life activities, such as early embryonic differentiation, development, cell proliferation, differentiation, apoptosis,
inflammation, and so on [40]. MiRNA also plays multiple roles in various aspects of cerebral ischemia, regulating apoptosis, differentiation, vascular inflammatory response, ischemia-reperfusion injury, and so on. Ouyang et al. found that the target protein of miR-181 is a classic marker of GRP78, endoplasmic reticulum stress. The expression of miR-181 decreases and GRP78 increases during cerebral ischemia, which mediates apoptosis and promotes the development of brain injury [41]. Other studies have confirmed that miR-181a inhibitor treatment can significantly reduce the area of cerebral infarction, reduce the loss of neurological function, reduce leukocyte infiltration, and protect against cerebral ischemic injury for a long time [42]. To explore the mechanism of ischemic injury of the brain, we constructed the mouse MCAO model, which is a commonly used animal model to detect cerebral ischemic diseases [43]. And FJC staining, TTC staining, and neurological grading scores were used to confirm the success of the MCAO model. To identify the regulating miRNA in cerebral infarction, we performed microarray and found a significant decrease of miR-542-3p in ischemic tissues. And the low expression of miR-542-3p in ischemic brain tissue has been shown in the previous study [44]. Interestingly, TLR4, which potentially binds with miR-542-3p, was increased in infarcted brain tissue. And we performed luciferase assay and RIP assay to confirm the relation between miR-542-3p and TLR4. Our data indicated an interaction of miR-542-3p and TLR4. TLR4 is a key receptor of innate immunity, which mediates inflammatory response in multiple organs [45].

Then, we aimed to determine the role of miR-542-3p in cerebral infarction. AAV9-miR-542-3p was constructed to force miR-542-3p level in brain tissues. Adeno-associated virus vector is a safe, durable, and efficient gene manipulation tool, which has been widely used in the field of neurobiology [46]. And in the present study, miR-542-3p level in brain tissues was prominently increased after AAV9-miR-542-3p injection. Then, we evaluated the function of miR-542-3p in infarcted brain, and our data showed that AAV9-miR-542-3p injection decreased infarcted size, reduced the number of degenerating neurons, and inhibited brain water content and neurological grading scores. Considering the key role of inflammation in cerebral infarction [48], we detected inflammatory response. Our results suggested that MCAO operation promoted the expression of inflammatory factors, and infiltration of inflammatory cells, while AAV9-miR-542-
3p injection suppressed MCAO-induced inflammation in brain tissues. Furthermore, human glial cell line HA1800 cells were treated with OGD to mimic brain ischemia, and HA1800 cells were transfected with miR-542-3p mimics. In consistent with the results of in vivo experiments, miR-542-3p mimics inhibited OGD-induced cell apoptosis, ROS production, and inflammation.

Exosomes are vesicles secreted by cells with phospholipid bilayers. Different from other extracellular vesicles with a diameter of 100–1000 nm, exosomes originate
directly from the cell membrane. Exosomes originate from the endosomal system of cells [45]. Exosomes mainly carry endogenous proteins, lipids, nucleic acids, and other substances, which are transmitted between cells through target cell internalization, receptor-ligand interaction, or lipid membrane fusion [49]. In 2007, Valadi et al. confirmed for the first time the existence of RNA in exosomes, including mRNA, miRNA, and some non-coding RNA [50]. Exosomes can also carry proteins and peptides. Through proteome analysis, Laura Otero-Ortega’s team has identified 2416 proteins in exosomes derived from MSCs, which are fully involved in molecular regulation, binding, and catalytic functions [51]. In addition, exosomes contain proteins involved in brain repair, including synaptic transmission, neural differentiation of neural stem cells, angiogenesis, neural projection, synaptic growth and so on. Studies have shown that after MSCs treatment, miR-133b levels are increased, and MSCs transmit miR-133b through exosomes to regulate nerve growth. MiR-133b overexpressed in exosomes secreted by MSCs can promote the recovery of nerve function and increase nerve plasticity by stimulating secondary secretion of exosomes from astrocytes [52]. MiR-17-92 derived from exosomes of MSCs promotes nerve recovery and neuroplasticity by activating PI3K/Akt/mTOR/GSK-3β signaling pathway [53]. These evidences indicate the important role of MSC exosome-derived miRNAs in cerebral ischemia, and we wondered whether miR-542-3p can be enveloped in MSCs and then secreted via exosomes. Exosomes were isolated from MSCs transfected with miR-542-3p, and we found a high expression of miR-542-3p in exosomes of MSCs supernatant, which revealed that miR-542-3p was packaged into exosomes and secreted into supernatant by MSCs. Moreover, exo-miR-542-3p exerted a protective role in MCAO-induced injury and OGD-treated HA1800 cells via modulating TLR4.

It has been proved that MSCs from different tissue sources can enhance the recovery of neurological function in animal models of stroke. Despite these findings, the difficulty of treatment in patients with acute stroke,
the risk of MSCs transplantation, and the high cost of maintaining stem cell activity limit the use of MSCs. In recent years, exosome has attracted wide attention because of its unique characteristics in the diagnosis and treatment of stroke. Because there is not enough clinical data to support the clinical application of exosome therapy, the diagnosis and treatment of exosomes is still in the theoretical and experimental stage.

Conclusion
In summary, MSC-derived exosome miR-542-3p prevented ischemia-induced glial cell inflammatory response via inhibiting TLR4. This results suggest possible therapeutic strategies for using exosome delivery of miR-542-3p to cure cerebral ischemic injury.

Abbreviations
MSCs: Mesenchymal stem cells; TLR4: Toll-Like Receptor 4; MCAO: Middle cerebral artery occlusion; OGD: Oxygen and glucose deprivation; TEM: Transmission electron microscopy; ROS: Reactive oxygen species; FJC: Fluoro-Jade C; AAV9: Adeno-associated virus 9

Acknowledgements
Not applicable.

Authors’ contributions
Dianquan Zhang, Guoliang Cai, Haiqun Zhou, Zhe Zhan, Xiaochun Li, and Siying Pei performed the majority of experiments and analyzed the data. Yanan Wang, Hong Wang, Xin Wang, and Shengnian Li performed molecular investigations; Cheng Cui, Manchao Sun, and Shihui Guo designed and coordinated the research; Kunping Jia, Xiuzhen Wang and Guofeng Cai wrote the paper. The authors read and approved the final manuscript.

Funding
This study was supported by National Science Foundation of Heilongjiang Province (H2018066), Scientific Research Fund of Heilongjiang University of Traditional Chinese Medicine (2020KYXJJ001), and State Administration of Traditional Chinese Medicine of Heilongjiang Province, No. ZHY16-027.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The Ethics Committee of this study was approved by the Animal Care and Use Committee of the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Hanan Branch of Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin 150001, China. 2Department of Sport Science and Health, Harbin Sport University, Harbin 150008, China. 3Heilongjiang University of Traditional Chinese Medicine, Harbin 150001, China. 4Department of Rehabilitation Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong Province, China.

References
1. Marin C, Tozato R, De Santis F, Ciancaelli I, Baldassarre M. Stroke in young adults in the community-based L’Aquila registry: incidence and prognosis. Stroke. 2003;32(15):6-4.
2. Burke J, Lisabeth L, Brown D, Reeves M, Morganstern H. Determining stroke’s rank as a cause of death using multicause mortality data. Stroke. 2012;43(8):2207–11.
3. Wang Y, Jin H, Wang W, Wang F, Zhao H. Myosin1f-mediated neutrophil migration contributes to acute neutrophil infiltration and brain injury after stroke in mice. J Neuroinflammation. 2019;16:83.
4. Waksho D, Scharkowski F, Carleo J, Jones B, Bart U, Bansal V, Steinkner-Kumar A, et al. Functional hypoxia preserves neurogenesis and neurogenesis by brain erythropoietin. Nat Commun. 2020;11(1):1313.
5. Hayashi Y, Jinnou H, Sawamoto T, Shishido S. Adult neurogenesis and its role in brain injury and psychiatric diseases. J Neurochem. 2018;147(5):584–94.
6. Smith M, Reddy L, Rani C, Sharma D, Citerio G. Acute ischemic stroke: challenges for the future. Intensive Care Med. 2019;45(9):1177–89.
7. Li W, He T, Jiang L, Shi L, Song Y, Mamtihani M, et al. Fingolimod inhibits inflammation and exacerbates brain edema in the acute phases of cerebral ischemia in adult mice. Front Neurosci. 2020;14:842.
8. Thunhavik J, Chattipakorn N, Chattipakorn S. The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion. J Cell Physiol. 2020.
9. Lu L, Jiang C, Chen J, Shi J, Li X, Wang Y, et al. Synthesis and biological evaluation of 1,2,4-triazole derivatives as potential neuroprotectant against ischemic brain injury. Eur J Med Chem. 2020;190:112114.
10. Yang M, Yu Q, Huang Y, Yang G. Neuroprotective effects of andrographolide derivative CX-10 in transient focal ischemia in rats: involvement of Nrf2/ARE and TLR/NF-kB signaling. Pharmacol Res. 2019;144:227–34.
11. Qin Y, Hu W, Yang Y, Hu Z, Li W, Fang M. Neuroprotective effect of DAHP via antiapoptosis in cerebral ischemia. Behav Neurol. 2018;2018:5050469.
12. Lehner M, Ittner J, Bundschuh D, van Rooijen N, Wendel A, Hartung T. Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infect Immun. 2001;69(1):463–71.
13. Zhang L, Xia R, Jia J, Wang L, Li K, Li Y, et al. Oleancolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 1A-activated calcium signals. Mol Immunol. 2018;99:99–103.
14. Jeske R, Bejoy J, Marzano M, Li Y. Human pluripotent stem cell-derived extracellular vesicles: characteristics and applications. Tissue Eng B Rev. 2020;26(2):129–44.
15. Cao J, Zhang M, Xie F, Lou J, Zhou X, Zhang L, et al. Exosomes in head and neck cancer: roles, mechanisms and applications. Cancer Lett. 2020;494:7–16.
16. Kim H, Kim T, Kang L, Kim Y, Kang M, Kim J, et al. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials. 2020;243:119442.
17. Luo X, Wang W, Li D, Xu C, Liao B, Li F, et al. Plasma exosomal miR-450b-5p as a possible biomarker and therapeutic target for transient ischaemic attacks in rats. J Molecular Neurosci. 2019;69(4):516–26.
18. Li Y, Wu J, Wang J, Hu X, Xiang D. Emerging strategies for labeling and tracking of extracellular vesicles. J Controlled Release. 2020;328:141–59.
19. Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, et al. MR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013;31(12):2737–46.
20. Anderson J, Johansson H, Graham C, Vesterlund M, Pham M, Bramlett C, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells. 2016;34(3):601–13.
21. Pan Q, Kuang X, Cai S, Wang X, Du D, Wang J, et al. miR-122-3p priming enhances the effects of mesenchymal stromal cell-derived exosomes on ameliorating brain ischemic injury. Stem Cell Res Ther. 2020;11(1):260.
22. Chen F, Liang P, Ye F, Hou C, Li P. Mesenchymal stem cell therapy for patients with ischemic heart failure—past, present, and future. Current Stem Cell Res Ther. 2020.
23. Ghafori-Fard S, Shoorei H, Taheri M. Non-coding RNAs participate in the ischemia-reperfusion injury. Biomedicine Pharmacotherapy. 2020;129:10419.

24. Chi W, Meng F, Li Y, Wang Q, Wang G, Han S, et al. Downregulation of miRNA-134 protects neural cells against ischemic injury in N2a cells and mouse brain with ischemic stroke by targeting HSPA12B. Neuroscience. 2014;277:111–22.

25. Sun Y, Gu H, Li Q, Luo Z, Zheng M, Duan J, et al. MicroRNA-124 protects neurons against apoptosis in cerebral ischemic stroke. CNS Neurosci Therapeutics. 2013;19(10):813–9.

26. Yan Y, Xia H, Hu J, Zhang B. MicroRNA-542-3p regulates P-glycoprotein expression in rat epipylegia via the toll-like receptor 4/nuclear factor-kappaB signaling pathway. Curr Neuropathol. 2019;8(1):433–40.

27. He W, Chen S, Chen X, Li S, Chen W. Bioinformatic analysis of potential microRNAs in ischemic stroke. J Stroke Cerebrovascular Dis. 2016;25(7):1753–9.

28. Dong X, Gao J, Zhang C, Hayworth C, Frank M, Wang Z. Neutrophil membrane-derived nanovesicles alleviate inflammation to protect mouse brain injury from ischemic stroke. ACS Nano. 2019;13(2):1272–83.

29. Egashira Y, Shishido H, Hua Y, Keep R, Xi G. New grading system based on magnetic resonance imaging in a mouse model of subarachnoid hemorrhage. Stroke. 2015;46(2):582–4.

30. Wang J, Doré S. Herne oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain. 2007;130:1643–52.

31. Zhao G, Liu F, Liu Z, Zuo K, Wang B, Zhang Y, et al. MSC-derived exosomes attenuate cell death through suppressing AIF nucleus translocation and enhance cutaneous wound healing. Stem Cell Res Ther. 2020;11(1):174.

32. Zhang X, Wang S, Wang H, Gao J, Huang X, Chen Z, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019;18(1):20.

33. Bowyer J, Robinson B, Ali S, Schmued L. Neurotoxic related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse (New York, NY). 2008;62(3):193–204.

34. Rahman A, Saleki K, Jianamehr N, Khodaparast J, Saadat P, Nouri H. Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous system vasculature systems in stroke. Ageing Res Rev. 2020;62:101106.

35. Zhao Y, Fang Y, Li J, Duan Y, Zhao H, Gao L, et al. Neuroprotective effects of Chrysophanol against inflammation in middle cerebral artery occlusion mice. Neurosci Lett. 2016;630:16–22.

36. Zhang H, Jiang L, Hou J, Zhong S, Zhao J, Yang D, et al. Exosomes: a novel mediator in drug resistance of cancer cells. Epigenomics. 2018;10(11):1499–509.

37. Simpson R, Lim J, Moritz R, Yakhchali J. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009;6(3):267–83.

38. Kabekkodu S, Shukla K, Vangheluwe T, Douzà J, Chakrabarty S, Satyanarorthy K. Clustered microRNAs with their regulatory biological functions and diseases. Biol Rev Camb Philos Soc. 2009;84(3):555–1986.

39. Soifer H, Rosenfeldt SA. MicroRNAs in disease and potential therapeutic application. Mol. Med. 2007;15(12):2007–9.

40. Hata A, Kanazawa R, D. Regulation of microRNA biogenesis machinery in cancer. Crit Rev Oncol Hematol. 2016;101(3):121–34.

41. Yuan Y, Lu Y, Song X, Xu L, Xiong W, White R, et al. mir-181 regulates non-alcoholic fatty liver disease outcome from cerebral ischemia in vitro and in vivo. Front Cell Dis. 2012;4(555):55–63.

42. Su Y, Yuan J, Zhang F, Lei Q, Zhang T, Li K, et al. MicroRNA-181a-3p and microRNA-181a-5p cooperatively restrict vascular inflammation and atherosclerosis. Cell Death Dis. 2019;10:536.

43. Wang D, Liu F, Zhu L, Lin P, Han F, Wang X, et al. FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. J Neuroinflammation. 2020;17:257.

44. Qu Y, Sun X, Yan X, Jin H, Guo Z, Yang Y. Identification of microRNAs and messenger RNAs involved in human umbilical cord mesenchymal stem cell treatment of ischemic cerebral infarction using integrated bioinformatics analysis. Neural Regen Res. 2019;14(9):1610–6.

45. Bruning E, Collier J, Wardill H, Bowen J. Site-specific contribution of toll-like receptor 4 to intestinal homeostasis and inflammatory disease. J Cell Physiol. 2020;236(2):877–88.

46. Sano H, Kobayashi K, Gómez de Frutos M, García F, Rodríguez-Frutos B, Medina-Gutiérrez E, López J, et al. Temporal control of microRNA biogenesis and spatial dynamics of microglia/macrophages. J Neuroinflammation. 2020;17(1):257.